Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hepatitic B Vaccines
New research on hepatitic b vaccines from J. Beran and co-authors summarized
March 26th, 2008
"High susceptibility to infections including the hepatitis B virus (HBV) causes increased morbidity and mortality in patients with end stage renal disease. HBV vaccination is recommended for all patients undergoing dialysis; however, antibody response is much lower than in healthy individuals," scientists in Czech Republic report. "This review discusses the clinical experience with HBV vaccine with a novel adjuvant system among dialysed patients. A new adjuvanted HBV vaccine (Fendrix (TM), GlaxoSmithKline Biologicals, Rixensart, Belgium) contains as active substance 20 mu g recombinant hepatitis B surface antigen produced in Saccharomyces cerevisiae and the novel...
Source: Vaccine Weekly (2008-03-26)
|
